Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint

Annals of Neurology

Volumn 69, Issue 2, 2011, Pages 424-

  Nyholm, Dag ^a   Askmark, Håkan ^a   Aquilonius, Sten Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA;

DRUG BLOOD LEVEL; DYSKINESIA; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

ANTIPARKINSON AGENTS; CATECHOLS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; NITRILES; PARKINSON DISEASE;

EID: 79952521082     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22257     Document Type: Letter

References (5)

1. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18-27.
2. Nyholm D,. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006; 45: 109-136. (Pubitemid 43290827)
3. Kuoppamaki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009; 65: 443-455.
4. Olanow CW, Stocchi F,. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004; 62 (suppl 1): S72-S81. (Pubitemid 38082855)
5. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156-163. (Pubitemid 36676295)